Stock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook

Stock Track

27 Feb

BeiGene Ltd (NASDAQ: ONC) stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.

The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.04 billion.

For the full year 2024, BeiGene's total revenue reached $3.81 billion, up 55% year-over-year, fueled by the strong performance of BRUKINSA in the U.S. and Europe. The company achieved positive non-GAAP operating income for the full year, despite reporting a GAAP operating loss.

Looking ahead, BeiGene provided an optimistic outlook for 2025, projecting total revenue between $4.9 billion and $5.3 billion, exceeding analysts' expectations of $4.73 billion. The company expects to achieve positive GAAP operating income and generate positive cash flow from operations in 2025, driven by BRUKINSA's continued leadership position in the U.S. and global expansion.

BeiGene's management highlighted the company's progress in advancing its solid tumor pipeline, with multiple data readouts anticipated in the first half of 2025. The company also emphasized its commitment to developing innovative and accessible cancer treatments worldwide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191662413"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191662413\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191662413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191662413","market":"hk","top_or_hot":-1,"title":"Stock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook","media":"Stock Track","content":"<p>BeiGene Ltd (NASDAQ: ONC) stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.</p>\n\n<p>The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.04 billion.</p>\n\n<p>For the full year 2024, BeiGene's total revenue reached $3.81 billion, up 55% year-over-year, fueled by the strong performance of BRUKINSA in the U.S. and Europe. The company achieved positive non-GAAP operating income for the full year, despite reporting a GAAP operating loss.</p>\n\n<p>Looking ahead, BeiGene provided an optimistic outlook for 2025, projecting total revenue between $4.9 billion and $5.3 billion, exceeding analysts' expectations of $4.73 billion. The company expects to achieve positive GAAP operating income and generate positive cash flow from operations in 2025, driven by BRUKINSA's continued leadership position in the U.S. and global expansion.</p>\n\n<p>BeiGene's management highlighted the company's progress in advancing its solid tumor pipeline, with multiple data readouts anticipated in the first half of 2025. The company also emphasized its commitment to developing innovative and accessible cancer treatments worldwide.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Soars Over 5% as Q4 Results Beat Estimates, Upbeat 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene Ltd (NASDAQ: ONC) stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.</p>\n\n<p>The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.04 billion.</p>\n\n<p>For the full year 2024, BeiGene's total revenue reached $3.81 billion, up 55% year-over-year, fueled by the strong performance of BRUKINSA in the U.S. and Europe. The company achieved positive non-GAAP operating income for the full year, despite reporting a GAAP operating loss.</p>\n\n<p>Looking ahead, BeiGene provided an optimistic outlook for 2025, projecting total revenue between $4.9 billion and $5.3 billion, exceeding analysts' expectations of $4.73 billion. The company expects to achieve positive GAAP operating income and generate positive cash flow from operations in 2025, driven by BRUKINSA's continued leadership position in the U.S. and global expansion.</p>\n\n<p>BeiGene's management highlighted the company's progress in advancing its solid tumor pipeline, with multiple data readouts anticipated in the first half of 2025. The company also emphasized its commitment to developing innovative and accessible cancer treatments worldwide.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1191662413","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191662413","pubTimestamp":1740661360,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeiGene Ltd  stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"第四季度业绩超出预期，2025年前景乐观，百济神州股价飙升逾5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeiGene Ltd (NASDAQ: ONC) stock soared 5.79% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial results for the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025.\nThe global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from the year-ago period, surpassing analyst estimates of $1.04 billion.\nFor the full year 2024, BeiGene's total revenue reached $3.81 billion, up 55% year-over-year, fueled by the strong performance of BRUKINSA in the U.S. and Europe. The company achieved positive non-GAAP operating income for the full year, despite reporting a GAAP operating loss.\nLooking ahead, BeiGene provided an optimistic outlook for 2025, projecting total revenue between $4.9 billion and $5.3 billion, exceeding analysts' expectations of $4.73 billion. The company expects to achieve positive GAAP operating income and generate positive cash flow from operations in 2025, driven by BRUKINSA's continued leadership position in the U.S. and global expansion.\nBeiGene's management highlighted the company's progress in advancing its solid tumor pipeline, with multiple data readouts anticipated in the first half of 2025. The company also emphasized its commitment to developing innovative and accessible cancer treatments worldwide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}